"Eli Lilly's revenue hit $19.80 billion, beating estimates by 11.25% and growing 55.5% year over year. Non-GAAP EPS came in at $8.55 versus a $6.79 consensus, a 25.88% beat."
"CEO David Ricks highlighted the U.S. FDA approval of Foundayo, the only approved GLP-1 pill that can be taken any time of day, significantly expanding the addressable obesity market."
"Our bull-case scenario takes shares to $1,219.94, a 30.53% total return. Analyst consensus already sits at $1,202.34 with 24 buy ratings against one sell."
Eli Lilly reported a remarkable first quarter with revenue of $19.80 billion, exceeding estimates by 11.25% and growing 55.5% year over year. The company raised its full-year revenue guidance to $82 billion to $85 billion. Despite a year-to-date decline of 12.89%, shares surged 9.8% following the earnings report. Analysts project a price target of $1,133.12, indicating a 21.24% upside. Risks include a 13% drop in realized prices due to rebates and access agreements affecting Mounjaro and Zepbound.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]